Xeljanz: FDA issues safety alert when given in higher doses in RA patients
by Press Release from Outbreak News Today on (#49WWE)
The US Food and Drug Administration (FDA) issued a safety alert today concerning the dosing of the rheumatoid arthritis (RA) drug, Xeljanz and Xeljanz XR. A safety clinical trial found an increased risk of blood clots in the lungs and death when a 10 mg twice daily dose of tofacitinib, the active ingredient in Xeljanz was used ["]
The post Xeljanz: FDA issues safety alert when given in higher doses in RA patients appeared first on Outbreak News Today.